Tweet
Chest. Chronic Macrolide Therapy in Inflammatory Airways Diseases
Chronic Macrolide Therapy in Inflammatory Airways Diseases (CHEST, abstract, edited)
[Source: Chest, full text: <cite cite="http://chestjournal.chestpubs.org/content/138/5/1202.short?rss=1">Chronic Macrolide Therapy in Inflammatory Airways Diseases ? CHEST</cite>. Abstract, edited.]
Chronic Macrolide Therapy in Inflammatory Airways Diseases
1. Adam L. Friedlander, MD and 2. Richard K. Albert, MD, FCCP
Author Affiliations
1. From the Division of Pulmonary Sciences and Critical Care Medicine (Drs Friedlander and Albert), and the Department of Medicine, Denver Health (Dr Albert), Department of Medicine, University of Colorado Denver Health Sciences Center; and the Department of Medicine (Dr Friedlander), National Jewish Health, Denver, CO.
1. Correspondence to: Adam L. Friedlander, MD, National Jewish Health, 1400 Jackson St, Denver, CO 80206; e-mail: Adam.Friedlander@UCDenver.edu
Abstract
Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of antiinflammatory properties in addition to being antimicrobials. These observations provided the rationale for many studies performed over the last decade to assess the usefulness of macrolides in other inflammatory airways diseases, such as cystic fibrosis, asthma, COPD, and bronchiolitis obliterans syndrome. This review summarizes the immunomodulatory properties of macrolides and the results of these recent studies demonstrating their potential for being disease-modifying agents.
Footnotes
* Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
#Abbreviations: AECOPD acute exacerbation of COPD, BALF BAL fluid, BOOP bronchiolitis obliterans organizing pneumonia, BOS bronchiolitis obliterans syndrome, CF cystic fibrosis, DPB diffuse panbronchiolitis, TNF-α tumor necrosis factor α
* Received January 22, 2010.
* Accepted May 27, 2010.
* ? 2010 American College of Chest Physicians
-
------
[Source: Chest, full text: <cite cite="http://chestjournal.chestpubs.org/content/138/5/1202.short?rss=1">Chronic Macrolide Therapy in Inflammatory Airways Diseases ? CHEST</cite>. Abstract, edited.]
Chronic Macrolide Therapy in Inflammatory Airways Diseases
1. Adam L. Friedlander, MD and 2. Richard K. Albert, MD, FCCP
Author Affiliations
1. From the Division of Pulmonary Sciences and Critical Care Medicine (Drs Friedlander and Albert), and the Department of Medicine, Denver Health (Dr Albert), Department of Medicine, University of Colorado Denver Health Sciences Center; and the Department of Medicine (Dr Friedlander), National Jewish Health, Denver, CO.
1. Correspondence to: Adam L. Friedlander, MD, National Jewish Health, 1400 Jackson St, Denver, CO 80206; e-mail: Adam.Friedlander@UCDenver.edu
Abstract
Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of antiinflammatory properties in addition to being antimicrobials. These observations provided the rationale for many studies performed over the last decade to assess the usefulness of macrolides in other inflammatory airways diseases, such as cystic fibrosis, asthma, COPD, and bronchiolitis obliterans syndrome. This review summarizes the immunomodulatory properties of macrolides and the results of these recent studies demonstrating their potential for being disease-modifying agents.
Footnotes
* Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
#Abbreviations: AECOPD acute exacerbation of COPD, BALF BAL fluid, BOOP bronchiolitis obliterans organizing pneumonia, BOS bronchiolitis obliterans syndrome, CF cystic fibrosis, DPB diffuse panbronchiolitis, TNF-α tumor necrosis factor α
* Received January 22, 2010.
* Accepted May 27, 2010.
* ? 2010 American College of Chest Physicians
-
------